Expert Interviews
Prithviraj Bose, MD, unpacks key highlights in MPN treatment and research at ASH 2024.
Amy Pierre, RN, BSN, ANP-BC, explains why it's important for advanced practice nurses to be invovled in research.
Lisa Hwa, APRN, CNP, DNP, MS, is a member of the ASH Medical Educators Institute and has presented multiple ASH abstracts.
Beth Faiman, PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO, shares her hopes for the new year.
Pierluigi Porcu, MD, discusses the phase II Tellomak trial and how nurses can help patients manage this rare disease.
Amy Pierre, RN, BSN, ANP-BC, reflects on highlights from ASH 2024 and why it's critical for advanced practitioners to attend.
An expert in pediatric GVHD shares his hopes and projections for the future of GVHD treatment and research.
Samantha Shenoy, NP, shares why it's important for nurses and APPs to consider attending the annual meeting.
Beth Faiman, PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO, discusses the significance of ASH 2024.
The CLL12 trial included patients with treatment-naive, asymptomatic, early-stage chronic lymphocytic leukemia.
Lisa Hwa, APRN, CNP, DNP, MS, discusses her work with the ASH Medical Educators Institute and her conference experience.
Amy Pierre, RN, BSN, ANP-BC, shares insights and key action items from her ASH 2024 presentation on the topic.
Richard Newcomb, MD, shares insights from his ASH 2024 presentation and explains why nurses play a major role in outcomes.
Irwin Walker, MBBS, shares how he's seen the meeting evolve since his first time attending in 1971.
Kirk R. Schultz, MD, FCAHS, explains that multiple strategies for GVHD prevention and preemption are under investigation.
Dr. Bose joined Cancer Nursing Today at ASH 2024 to share insights on using anemia-supporting medications with ruxolitinib.
Advertisement
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.